Fluidigm to Participate in Upcoming Health Care Investor Conferences
20 août 2019 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results
02 août 2019 00h41 HE
|
Fluidigm Corporation
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass...
Fluidigm Announces Second Quarter 2019 Financial Results
01 août 2019 16h05 HE
|
Fluidigm Corporation
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass...
Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019
20 juin 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry
28 mars 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System
25 oct. 2018 08h30 HE
|
Fluidigm Corporation
Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) --...